SWOG clinical trial number
SWOG-9415 (INT-0153) (CALGB-9498) (ECOG-S9415) (NCCTG-S9415)

Phase III Randomized Trial of 5-FU/Leucovorin/Levamisole versus 5-FU Continuous Infusion/Levamisole as Adjuvant Therapy for High-Risk Resectable Colon Cancer, Intergroup.

Abbreviated Title
High Risk Resectable Colon

Research committees

Gastrointestinal Cancer


5-Fluorouracil Leucovorin Calcium Levamisole

Publication Information Expand/Collapse


Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database

AD Wagner;A Grothey;T Andre;J Dixon;N Wolmark;D Haller;CJ Allegra;E VanCutsem;T George;A DeGramont;S Alberts;C Twelves;M O'Connell;L Saltz;C Blanke;G Francini;R Kerr;R Goldberg;G Yothers;Q Shi J Clin Oncol 36, 2018 (suppl; abstr 3603); ASCO 2018 Annual Meeting (June 1-5, 2018, Chicago, IL), poster session

The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster


Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials

A Barzi;D Hershman;C Till;H Lenz;H Hochster;W Barlow;J Unger J Clin Oncol 35, 2017 (suppl; abstr 10056); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session


Determinants of early mortality among 37,568 patients with colon cancer who participated in 25 clinical trials from the Adjuvant Colon Cancer Endpoints Database

WY Cheung;LA Renfro;D Kerr;A de Gramont;LB Saltz;A Grothey;SR Alberts;T Andre;KA Guthrie;R LaBianca;G Francini;J-F Seitz;C O'Callaghan;C Twelves;E Van Cutsem;DG Haller;G Yothers;DJ Sargent Journal of Clinical Oncology, Apr 10;34(11):1182-1189

PMid: PMID26858337 | PMC number: PMC4933130

Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database

D Papamichael;LA Renfro;C Matthaiou;G Yothers;L Saltz;KA Guthrie;E Van Cutsem;H Schmoll;R Labianca;T Andre;M O'Connell;SR Alberts;DG Haller;P Kountourakis;D Sargent Journal of Geriatric Oncology 2016 Jul 25. pii: S1879-4068(16)30088-1. doi: 10.1016/j.jgo.2016.07.002 Jul 25 [Epub ahead of print]

PMid: PMID27468630 | PMC number: PMC5159186


Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population [Collaborators: K Guthrie, C Blanke] (https://www.ncbi.nlm.nih.gov/pubmed/25697217)

LA Renfro;A Grothey;D Kerr;DG Haller;T Andre;E Van Cutsem;L Saltz;R Labianca;CL Loprinzi;SR Alberts;H Schmoll;C Twelves;G Yothers;DJ Sargent Annals of Oncology May;26(5):950-958; 2015

PMid: PMID25697217 | PMC number: PMC4405281


Modeling the relationship between progression-free survival and overall survival: the phase 2/3 trial

M Redman;B Goldman;M LeBlanc;A Schott;LH Baker Clinical Cancer Research, 19(10):2646-2656;

PMid: PMID23669424 | PMC number: PMC4131693

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database

W Cheung;Q Shi;M O'Connell;J Cassidy;CD Blanke;DJ Kerr;J Meyers;E Van Cutsem;SR Alberts;G Yothers;D Sargent Clinical Colorectal Cancer 12(3):179-187

PMid: PMID23810482 | PMC number: PMC3760214

Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database

Q Shi;T Andre;A Grothey;G Yothers;SR Hamilton;BM Bot;DG Haller;E van Cutsem;C Twelves;J Benedetti;MJ O'Connell;DJ Sargent Journal of Clinical Oncology 31(29):3656-3663

PMid: PMID23980089 | PMC number: PMC3804289


Outcomes among black patients with stage II/III colon cancer receiving adjuvant chemotherapy: an accent group analysis [PMID21997132; PMC3196480]

G Yothers;D Sargent;N Wolmark;R Goldberg;M O'Connell;J Benedetti;L Saltz;J Dignam;A Blackstock Journal of the National Cancer Institute 103(20):1498-1506; JAMA


Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set [PMC2815708; PMID20008641]

A de Gramont;J Hubbard;Q Shi;M O'Connell;M Buyse;J Benedetti;B Bott;C O'Callaghan;G Yothers;RM Goldberg;CD Blanke;A Benson;Q Deng;S Alberts;T Andre;N Wolmark;A Grothey;D Sargent Journal of Clinical Oncology 28(3):460-465

Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) - findings from the ACCENT dataset

T Andre;Q Shi;G Yothers;BM Bott;G Haller;E Van Cutsem;J Cassidy;J Benedetti;M O'Connell;DJ Sargent Journal of Clinical Oncology 28:15s (suppl; abstr 3616); ASCO Annual Meeting; poster

Obesity is an independent prognostic variable in colon cancer survivors [PMID20215553; PMC2948494]

F Sinicrope;NR Foster;DJ Sargent;MJ O'Connell;C Rankin Clinical Cancer Research 16(6):1884-1893


Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set [PMID:18467725]

MJ O'Connell;ME Campbell;R Goldberg;A Grothey;J Seitz;JK Benedetti;T Andre;DG Haller;DJ Sargent Journal of Clinical Oncology 26(14):2336-2341


End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the Accent group [PMID17876008]

DJ Sargent;S Patiyil;G Yothers;DG Haller;R Gray;J Benedetti;M Buyse;R Labianca;JF Seitz;C O'Callaghan;G Francini;A Grothey;M O'Connell;PJ Catalano;D Kerr;E Green;HS Wieand;RM Goldberg;de Gramont Journal of Clinical Oncology 25(29):4569-4574


Phase III Southwest Oncology Group 9415/ Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer

EA Poplin;JK Benedetti;NC Estes;DG Haller;RJ Mayer;RM Goldberg;GR Weiss;SE Rivkin;JS Macdonald Journal of Clinical Oncology 23(9):1819-1825


Phase III randomized trial of bolus 5-FU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153)

E Poplin;J Benedetti;N Estes;D Haller;R Mayer;R Goldberg;J Macdonald Proc of the American Society of Clinical Oncology 19:240a(#931)

Other Clinical Trials

SWOG Clinical Trial Number

Investigation of Thioredoxin-1 Family Protein Expression in Rectal Cancer

Research Committee(s)
Gastrointestinal Cancer
SWOG Clinical Trial Number

Combined Therapies for Squamous Cell Carcinoma of the Esophagus

Research Committee(s)
Gastrointestinal Cancer
SWOG Clinical Trial Number
SWOG-8591(NCI Intergroup #0035)

An Evaluation of Levamisole Alone or Levamisole plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon

Research Committee(s)
Gastrointestinal Cancer